Roche to present latest oncology advances during ESMO 2014 Congress
Posted: 17 September 2014 | | No comments yet
Roche announced that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain. More than 160 abstracts related to Roche medicines across 15 cancer types have been accepted for presentation during the congress. These presentations include one late-breaking abstract as well as 27 oral presentations, two of which are featured in the congress Presidential Symposia.
“The data that will be presented at this year’s meeting show that cancer therapies can have even greater impact for patients when we understand which people will benefit the most from our medicines,” said Sandra Horning, Chief Medical Officer and Head, Global Product Development. “Data from many of Roche’s targeted medicines and combination approaches are being featured at ESMO this year, delivering insights about what may soon be possible for patients.”
Further information about Roche’s contribution to the ESMO 2014 scientific program and wider progress in cancer care will be made available during a Roche Media Briefing from 15:30 – 17:00 CEST on Friday 26th September at the Hotel Meliá Castilla, Madrid. Please note that this event is independently organised by Roche and is not sponsored by ESMO. To register please use the following link: http://roche.cvent.com/MediaBriefing2014.
Follow Roche on Twitter via @roche and keep up to date with ESMO 2014 Congress news and updates by using the hashtag #ESMO14.
Overview of key presentations featuring Roche medicines:
| Medicine | Description of study | Abstract number |
|---|---|---|
| Avastin (bevacizumab) + Xeloda (capecitabine) | Efficacy and safety of maintenance bevacizumab (BEV) with or without capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer (mBC): IMELDA randomised phase III trial Efficacy and safety in TANIA, a randomised phase III trial of continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) | #352O #353O |
| Perjeta (pertuzumab) + Herceptin (trastuzumab) | Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC) | #350O_PR Presidential Symposium 1, Sunday 28 September, 16:00 |
| Cobimetinib (investigational MEK inhibitor) + Zelboraf (vemurafenib) | Phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) | #LBA5_PR Presidential Symposium 2, Monday 29 September, 16:00 |
| MPDL3280A (investigational anti-PDL1) | Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or chemotherapy (chemo) in patients (pts) with locally advanced or metastatic solid tumours Inhibition of PD-L1 by MPDL3280A leads to clinical activity in pts with metastatic urothelial bladder cancer (UBC) Immune correlates and long term follow up of a Phase Ia study of MPDL3280A, an engineered [anti]PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC) | #1049O #808O #809O |
